ATE543513T1 - Anti-coronavirus impfstoff - Google Patents

Anti-coronavirus impfstoff

Info

Publication number
ATE543513T1
ATE543513T1 AT02772497T AT02772497T ATE543513T1 AT E543513 T1 ATE543513 T1 AT E543513T1 AT 02772497 T AT02772497 T AT 02772497T AT 02772497 T AT02772497 T AT 02772497T AT E543513 T1 ATE543513 T1 AT E543513T1
Authority
AT
Austria
Prior art keywords
vaccine
coronavirus
seq
peptide
protein
Prior art date
Application number
AT02772497T
Other languages
English (en)
Inventor
Andre Aubert
Veronique Duquesne
Marc Eloit
Valerie Gonon
Original Assignee
Virbac
Agronomique Inst Nat Rech
Envt Toulouse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virbac, Agronomique Inst Nat Rech, Envt Toulouse filed Critical Virbac
Application granted granted Critical
Publication of ATE543513T1 publication Critical patent/ATE543513T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT02772497T 2001-08-09 2002-08-09 Anti-coronavirus impfstoff ATE543513T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0110644A FR2828405B1 (fr) 2001-08-09 2001-08-09 Vaccin anti-coronavirus
PCT/FR2002/002843 WO2003013599A2 (fr) 2001-08-09 2002-08-09 Vaccin anti-coronavirus.

Publications (1)

Publication Number Publication Date
ATE543513T1 true ATE543513T1 (de) 2012-02-15

Family

ID=8866412

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02772497T ATE543513T1 (de) 2001-08-09 2002-08-09 Anti-coronavirus impfstoff

Country Status (5)

Country Link
US (1) US20050053622A1 (de)
EP (1) EP1429803B1 (de)
AT (1) ATE543513T1 (de)
FR (1) FR2828405B1 (de)
WO (1) WO2003013599A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004228584A1 (en) * 2003-04-08 2004-10-21 Coronovative B.V. Severe acute respiratory syndrome (SARS) causing coronavirus
EP1633775A2 (de) * 2003-06-13 2006-03-15 Crucell Holland B.V. Antigene peptide des sars-coronavirus und anwendungen davon
SG128680A1 (en) 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
TW200515917A (en) * 2003-09-15 2005-05-16 Us Government Methods and compositions for the generation of a protective immune response against SARS-COV
US8106170B2 (en) 2004-11-11 2012-01-31 Crucell Holland B.V. Compositions against SARS-coronavirus and uses thereof
EP1907536B1 (de) 2005-07-22 2010-04-07 Crucell Holland B.V. Zelllinie zur produktion von coronaviren
US8490489B2 (en) * 2006-11-10 2013-07-23 Siemens Medical Solutions Usa, Inc. Transducer array imaging system
US20210268101A1 (en) * 2020-03-02 2021-09-02 Cel-Sci Corporation NOVEL PEPTIDES FOR VACCINATION AND TREATMENT OF 2019-nCoV INFECTIONS
CN114057844A (zh) * 2020-08-07 2022-02-18 清华大学 一种预防新型冠状病毒肺炎covid-19的多肽、免疫原性偶联物及其用途
CN113203854B (zh) * 2021-04-25 2023-04-28 龙岩学院 用于检测猫冠状病毒抗体的间接elisa试剂盒
WO2023001259A1 (zh) * 2021-07-23 2023-01-26 神州细胞工程有限公司 一种可诱导广谱中和活性重组多价新冠病毒三聚体蛋白疫苗的制备及应用
CN118005750B (zh) * 2024-04-09 2024-06-25 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 猫冠状病毒核衣壳蛋白的表位最小基序肽及其应用
CN121698997A (zh) * 2026-02-13 2026-03-20 北京溯本源和生物科技有限公司 一种用于检测猫冠状病毒np蛋白单克隆抗体组合及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057436A (en) * 1990-11-14 2000-05-02 Pfizer Inc. Canine coronavirus S gene and uses therefor
ES2182827T3 (es) 1992-05-08 2003-03-16 Pfizer Gen del virus corona canino y usos del mismo.
JPH07508176A (ja) * 1992-05-08 1995-09-14 ファイザー・インコーポレイテッド 普遍コロナウイルスワクチン
FR2724385B1 (fr) * 1994-08-29 1996-12-13 Rhone Merieux Vaccin de la peritonite infectieuse feline.

Also Published As

Publication number Publication date
WO2003013599A2 (fr) 2003-02-20
WO2003013599A3 (fr) 2004-04-08
FR2828405B1 (fr) 2005-06-24
US20050053622A1 (en) 2005-03-10
EP1429803A2 (de) 2004-06-23
EP1429803B1 (de) 2012-02-01
FR2828405A1 (fr) 2003-02-14

Similar Documents

Publication Publication Date Title
CY1106875T1 (el) Αντιγονικα πεπτιδια απο neisseria
ATE543513T1 (de) Anti-coronavirus impfstoff
DE69936977D1 (de) Durch polynukleinsäuren vom reproduktiven und respiratorischen syndromvirus des schweines kodierte proteine
ATE430200T1 (de) Impstoff gegen den für atemwegs- und reproduktionserkrankungen beim schwein verantwortlichen virus
FR2741806B1 (fr) Vaccin vivant recombinant a base d'herpesvirus felin de type 1, notamment contre la peritonite infectieuse feline
WO2001045639A3 (en) Methods for protecting against lethal infection with bacillus anthracis
SG144692A1 (en) Antigenic proteins of shrimp white spot syndrome virus and uses thereof
ATE495247T1 (de) Chromoprotein und fluoroproteine
EP0652287A3 (de) Poxvirusvektoren und deren Anwendung als Impstoff gegen Katzenansteckende Peritonitis-Viruskrankheit.
ATE447612T1 (de) Fluoreszenzproteine
MXPA06013388A (es) Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
FR2769916B1 (fr) Peptides issus du gene env du virus de l'immunodeficience feline et leurs applications immunoprotectrices et vaccinales
AU686000B2 (en) Infectious peritonitis vaccine
EE200000478A (et) Peptiid, seda kodeeriv geen, diagnostiline reagent ja diagnostiline reaktiivikomplekt ning vaktsiinkasutamiseks riketsioosi ravis
WO1998040497A3 (en) An ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in said method
AU2003281917A8 (en) Vaccine against infections caused by oncoviruses such as the feline leucosis virus of cats
DK1425295T3 (da) Modificerede peptider og deres anvendelse til behandling af autoimmune sygdomme
WO2003064446A3 (en) Plasma protein-binding peptides from bacterial curli
WO2006113782A3 (en) Lawsonia protein useful as a component in subunit vaccine and methods of making and using thereof
NZ512308A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
DE60036676D1 (de) G-protein-gekoppelter rezeptor-ähnliche proteine
EP0949333A4 (de) Mutierte antigene des masernvirus und die dafür kodierenden gene.
DE60112994D1 (de) Menschlicher Cysteinyl Leukotrien Rezeptor 2 (CysLT2)
TH23725A (th) วัคซีนป้องกันโรคบิดสำหรับสัตว์ปีก